Unknown

Dataset Information

0

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.


ABSTRACT: Clinical Trials Registration:NCT02263326.

SUBMITTER: Taiwo BO 

PROVIDER: S-EPMC5961309 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Taiwo Babafemi O BO   Marconi Vincent C VC   Berzins Baiba B   Moser Carlee B CB   Nyaku Amesika N AN   Fichtenbaum Carl J CJ   Benson Constance A CA   Wilkin Timothy T   Koletar Susan L SL   Colasanti Jonathan J   Acosta Edward P EP   Li Jonathan Z JZ   Sax Paul E PE  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20180501 11


<h4>Clinical trials registration</h4>NCT02263326. ...[more]

Similar Datasets

| S-EPMC7225620 | biostudies-literature
| S-EPMC5515053 | biostudies-literature
| S-EPMC6477973 | biostudies-literature
| S-EPMC7654764 | biostudies-literature
| S-EPMC6002106 | biostudies-literature
| S-EPMC7185366 | biostudies-literature
| S-EPMC4645960 | biostudies-literature
| S-EPMC5961075 | biostudies-literature
| S-EPMC7043729 | biostudies-literature
| S-EPMC5543662 | biostudies-literature